Rhythm Pharmaceuticals Shares Rise Following Reports of Potential Eli Lilly Acquisition Interest
Rhythm Pharmaceuticals (RYTM) shares increased by 5.4% following reports that pharmaceutical giant Eli Lilly (LLY) is evaluating potential takeover targets within the obesity market. According to reports, Rhythm and Viking Therapeutics (VKTX) are among the companies being considered as part of Eli Lilly's strategic expansion into weight-loss treatments. The speculation follows broader industry movement in the metabolic health sector, including recent reports regarding AstraZeneca (AZN) making bids for other assets. If an acquisition occurs, it could involve structured offers such as Contingent Value Rights (CVR), which are common in high-stakes pharmaceutical mergers to account for future clinical milestones.

Tickers: $AZN $LLY $RYTM $VKTX
Topics: Mergers and Acquisitions Obesity Drugs Pharmaceuticals